wo papers published in Nature Medicine on Monday raised concerns that using CRISPR-Cas9 to edit genes could increase the chances that cancer cells develop. The stocks of CRISPR Therapeutics(NASDAQ:CRSP), Editas Medicine(NASDAQ:EDIT), and Intellia Therapeutics(NASDAQ:NTLA)plunged on the news.